The man accused of assassinating UnitedHealthcare chief executive Brian Thompson on a Manhattan street in December 2024 will mount a psychiatric defence at his state murder trial, a New York judge disclosed on Wednesday. Luigi Mangione, 28, appeared in court in a dark suit and white shirt as Judge Gregory Carro revealed that the defence intends to argue Mangione was suffering from an extreme emotional disturbance at the time of the killing. The trial is scheduled to begin on 8 September, and the legal strategy, while carrying significant risks, could see a jury convict Mangione of the lesser charge of manslaughter rather than second-degree murder.

Mangione is accused of fatally shooting Thompson outside a Midtown hotel in a brazen attack that triggered a multi-state manhunt and captured global headlines. He was arrested days later at a McDonald’s in Altoona, Pennsylvania, where authorities recovered a notebook containing writings expressing deep hostility toward the health insurance industry and its executives. Earlier this year, Mangione’s legal team secured a significant procedural victory when a judge ruled that evidence seized during his Pennsylvania arrest—including the contents of his backpack and statements made to police—was inadmissible, on the grounds that he had been subjected to an unlawful search. That ruling has already narrowed the prosecution’s path.

Under New York law, the affirmative defence of extreme emotional disturbance differs fundamentally from an insanity plea. Rather than asserting a lack of criminal responsibility, it effectively admits the act but argues that the defendant’s mental state at the time was so profoundly impaired that it negates the intent required for murder. If a jury accepts the argument, Mangione would face a manslaughter conviction and a substantially lighter sentence. Legal analysts in New York caution, however, that the defence faces steep evidentiary hurdles: the burden falls on the defence to demonstrate that the disturbance was both genuine and extreme, and prosecutors are certain to challenge any psychiatric testimony with their own experts.

The case has resonated far beyond the United States, with media across Latin America, Europe, and the Asia-Pacific region following each development closely. Viewed from London, the proceedings tap into a broader international unease over corporate power in healthcare systems. In Brazil and Mexico, coverage has framed the trial as a flashpoint for public anger against private insurers. Australian and Chinese outlets have noted the unusual degree of public sympathy Mangione has attracted in some quarters, a phenomenon that complicates jury selection and underscores the political undercurrents of the trial. Italian and Swedish reports have emphasised the rarity of such a defence succeeding in high-profile cases.

As the September trial date approaches, the defence must now produce psychiatric records and expert reports to substantiate its claim. Judge Carro has ordered the unsealing of court filings related to the psychiatric defence, a move that will expose the contours of Mangione’s argument to public scrutiny. The prosecution, meanwhile, is expected to emphasise the calculated nature of the attack—the surveillance footage, the premeditated travel, the manifesto-like writings—to counter any suggestion of a spontaneous emotional collapse. Whether a Manhattan jury proves receptive to a defence that merges mental health claims with a backdrop of anti-corporate grievance will be one of the most closely watched questions in American criminal justice this year.